| Autor: |
Zhu, Xiao‐Bin, Xu, Yao‐Yao, Li, Liu‐Cheng, Sun, Jia‐Bin, Wang, Yu‐Zhen, Chen, Jie, Wang, Chen, Zhang, Su, Jin, Liang‐Yan |
| Předmět: |
|
| Zdroj: |
Drug Development Research; Feb2024, Vol. 85 Issue 1, p1-10, 10p |
| Abstrakt: |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has attracted lots of attention in preventing the clearance of plasma low‐density lipoprotein cholesterol (LDL‐C). PCSK9 inhibitors are developed to primarily reduce the cardiovascular risk by lowering LDL‐C level. Recently, a number of pleiotropic extrahepatic functions of PCSK9 beyond the regulation of cholesterol metabolism, particularly its effects on central nervous system (CNS) diseases have been increasingly identified. Emerging clinical evidence have revealed that PCSK9 may play a significant role in neurocognition, depression, Alzheimer's disease, and stroke. The focus of this review is to elucidate the functions of PCSK9 and highlight the effects of PCSK9 in CNS diseases, with the aim of identifying the potential risks that may arise from low PCSK9 level (variant or inhibitor) in the clinical practice. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text